Research on the Brain Network Effects of Yijinjing in the Treatment of Lumbar Disc Herniation Patients Based on Multimodal MRI and MRS Techniques

注册号:

Registration number:

ITMCTR2025000474

最近更新日期:

Date of Last Refreshed on:

2025-03-06

注册时间:

Date of Registration:

2025-03-06

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于多模态MRI和MRS技术对易筋经功法治疗腰椎间突出症患者的脑网络效应研究

Public title:

Research on the Brain Network Effects of Yijinjing in the Treatment of Lumbar Disc Herniation Patients Based on Multimodal MRI and MRS Techniques

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于多模态MRI和MRS技术对易筋经功法治疗腰椎间突出症患者的脑网络效应研究

Scientific title:

Research on the Brain Network Effects of Yijinjing in the Treatment of Lumbar Disc Herniation Patients Based on Multimodal MRI and MRS Techniques

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

利涛

研究负责人:

吕立江

Applicant:

Li Tao

Study leader:

Lv Lijiang

申请注册联系人电话:

Applicant telephone:

15869195127

研究负责人电话:

Study leader's telephone:

13958107858

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

litao20000227@163.com

研究负责人电子邮件:

Study leader's E-mail:

lvlijiang0288@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市西湖区莫干山路219号浙江中医药大学附属第三医院

研究负责人通讯地址:

浙江省杭州市西湖区莫干山路219号浙江中医药大学附属第三医院

Applicant address:

No. 219 Mo Gan Shan Road Hangzhou Xi Hu District The Third Affiliated Hospital of ZCMU

Study leader's address:

No. 219 Mo Gan Shan Road Hangzhou Xi Hu District The Third Affiliated Hospital of ZCMU

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江中医药大学附属第三医院

Applicant's institution:

The Third Affiliated Hospital of Zhejiang Chinese Medical University

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

ZSLL-KY-2024-051-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

浙江中医药大学附属第三医院医学伦理委员会

Name of the ethic committee:

The Ethics Committee of the Third Affiliated Hospital of ZCMU

伦理委员会批准日期:

Date of approved by ethic committee:

2024/6/24 0:00:00

伦理委员会联系人:

燕晴

Contact Name of the ethic committee:

Yan Qing

伦理委员会联系地址:

浙江省杭州市西湖区莫干山路219号浙江中医药大学附属第三医院

Contact Address of the ethic committee:

No. 219 Mo Gan Shan Road Hangzhou Xi Hu District The Third Affiliated Hospital of ZCMU

伦理委员会联系人电话:

Contact phone of the ethic committee:

88393504

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zslunli@163.com

研究实施负责(组长)单位:

浙江中医药大学附属第三医院

Primary sponsor:

The Third Affiliated Hospital of Zhejiang Chinese Medical University

研究实施负责(组长)单位地址:

浙江省杭州市西湖区莫干山路219号浙江中医药大学附属第三医院

Primary sponsor's address:

No. 219 Mo Gan Shan Road Hangzhou Xi Hu District The Third Affiliated Hospital of ZCMU

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

杭州市

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学附属第三医院

具体地址:

浙江省杭州市西湖区莫干山路219号浙江中医药大学附属第三医院

Institution
hospital:

The Third Affiliated Hospital of Zhejiang Chinese Medical University

Address:

No. 219 Mo Gan Shan Road Hangzhou Xi Hu District The Third Affiliated Hospital of ZCMU

经费或物资来源:

国家自然科学基金

Source(s) of funding:

General Program of National Natrural Science Foundation of China

研究疾病:

腰椎间盘突出症

研究疾病代码:

Target disease:

Lumbar Disc Herniation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

研究易筋经功法干预LDH镇痛的脑效应机制,通过应用多模态MRI和MRS技术,探讨易筋经功法对LDH镇痛作用的脑响应特征的相关性,为临床应用提供现代生物学理论依据。

Objectives of Study:

To study the mechanism of brain effect of Yijingjing exercise on LDH analgesia and to explore the correlation of brain response characteristics of Yijingjing exercise on LDH analgesia by applying multi-modal MRI and MRS Techniques so as to provide modern biological theoretical basis for clinical application.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1: 符合腰椎间盘突出症西医诊断标准患者(符合腰椎间盘突出神经根性疼痛诊断标准,并单侧神经根放射痛患者) 2: 右利手 3: 年龄18-65周岁(包含18和65周岁),性别不限。于受试前3天内无服用任何镇静药,受试前无任何不适感 4: 目测类比评分法疼痛评分≥4分者 5: 知情同意者(需签定知情同意书)

Inclusion criteria

1: Patients who meet the Western medical diagnostic criteria for lumbar disc herniation (fulfilling the diagnostic criteria for lumbar disc herniation with radicular pain and presenting with unilateral radicular radiating pain) 2: dextromanuality 3: Participants aged between 18 and 65 years inclusive with no restrictions on gender.No sedative had been taken within 3 days prior to the test and no discomfort had occurred before the test 4: visual analogue scale pain score ≥4 points 5: Informed consent (informed consent required)

排除标准:

1: 合并能引起腰痛的内科及妇科疾病:如肾炎、尿路结石、妇科炎症、子宫病变等 2: 合并心血管、脑血管、肝、肾等严重原发性疾病者 3: 神经官能症及精神病患者 4: 原发性坐骨神经痛、干性坐骨神经痛患者 5: 合并腰椎滑脱者 6: 腰椎肿瘤、结核患者 7: 意识障碍,严重视力、听力及失语障碍,以及其他健康评估都不能完成者;对MRI畏惧以及其他原因不能进行MRI扫描者 8: 腰椎间盘突出症中医辨证不属于“瘀血阻滞”证者 9: 确诊为腰椎间盘突出症但无临床症状者

Exclusion criteria:

1: Combined with medical and gynecological diseases that can cause low back pain: such as nephritis urinary calculus gynecological inflammation uterine disease etc 2: Complicated with cardiovascular cerebrovascular liver kidney and other serious primary diseases 3: Neurosis and psychosis 4: Patients with primary sciatica and dry sciatica 5: Patients with lumbar spondylolisthesis 6: Lumbar tumor tuberculosis patients 7: Individuals with impaired consciousness severe visual or auditory deficits aphasia or other conditions that preclude the completion of health assessments; as well as those who are unable to undergo MRI scanning due to fear of MRI or other reasons 8: Patients with lumbar disc herniation whose traditional Chinese medicine (TCM) syndrome differentiation does not fall under the category of "blood stasis and obstruction" pattern 9: Individuals diagnosed with lumbar disc herniation but who are asymptomatic

研究实施时间:

Study execute time:

From 2023-01-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2024-06-30

To      2025-12-31

干预措施:

Interventions:

组别:

健康组

样本量:

30

Group:

The healthy control group

Sample size:

干预措施:

不干预

干预措施代码:

Intervention:

nonintervention

Intervention code:

组别:

患者组

样本量:

30

Group:

The patient group

Sample size:

干预措施:

易筋经

干预措施代码:

Intervention:

Yijinjing

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江省

市(区县):

杭州市

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江中医药大学附属第三医院

单位级别:

省级公立三甲医院

Institution/hospital:

The Third Affiliated Hospital of Zhejiang Chinese Medical University

Level of the institution:

Provincial public tertiary hospital

测量指标:

Outcomes:

指标中文名:

视觉模拟量表

指标类型:

次要指标

Outcome:

visual analogue scale

Type:

Secondary indicator

测量时间点:

干预前后

测量方法:

患者填写

Measure time point of outcome:

Before and after intervention

Measure method:

Patient-completed

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-Rating Anxiety Scale

Type:

Secondary indicator

测量时间点:

干预前后

测量方法:

患者填写

Measure time point of outcome:

Before and after intervention

Measure method:

Patient-completed

指标中文名:

各脑区信号变化

指标类型:

主要指标

Outcome:

Signal changes in various brain regions

Type:

Primary indicator

测量时间点:

干预前后

测量方法:

磁共振

Measure time point of outcome:

Before and after intervention

Measure method:

Magnetic resonance

指标中文名:

日本骨科协会评估治疗分数

指标类型:

次要指标

Outcome:

The Japanese Orthopaedic Association (JOA) score

Type:

Secondary indicator

测量时间点:

干预前后

测量方法:

患者填写

Measure time point of outcome:

Before and after intervention

Measure method:

Patient-completed

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用随机对照研究设计,严格按照诊断标准、纳入标准和排除标准筛选病例,确定入组后,按照随机数字表随机分组,直到完成总观察例数后结束试验。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study adopts a randomized controlled trial (RCT) design. Cases were rigorously screened according to the diagnostic criteria inclusion criteria and exclusion criteria. After confirming enrollment participants were randomly assigned to groups using a random number table. The trial continued until the total number of required observations was completed at which point the study was concluded.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The ResMan Clinical Trial Public Management Platform"http://www.medresman.org.cn/uc/index.aspx"

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above